|Articles|December 27, 2017

Can Marijuana Slow the Process of Neurodegeneration in HIV Patients?

Author(s)Kristi Rosa

A new study finds that THC found in marijuana could potentially slow the process of neurodegeneration in individuals with HIV.

A new study out of Michigan State University has found that tetrahydrocannabinol (THC), a chemical found in marijuana, could be beneficial for individuals living with HIV in that it can potentially slow the process of neurodegeneration within this population.

Neurodegeneration occurs in about 50% of HIV patients, according to the official university press release. According to Norbert Kaminski, PhD, lead author of the study, director for the Institute for Integrative Toxicology, and professor of Pharmacology and Toxicology, this may be because chronic inflammation that occurs in the brain of those who are infected.

“This happens because the immune system is constantly being stimulated to fight off disease,” Dr. Kaminski said in the press release. In healthy individuals, around 5% to 15% of their monocytes express inflammation markers, Dr. Kaminski told our sister publication MD Magazine, whereas, in those with HIV, 40% to 60% of their monocytes express these markers. This can result in a “great variation of cognitive issues” for those with HIV.

HIV infection is known to target the central nervous system in subcortical regions of the brain, which can result in high rates of delirium, depression, opportunistic central nervous system infections, and dementia.

“It can really run the gamut, from being relatively mild, to, in extreme cases, what you observe in an Alzheimer’s patient,” Dr. Kaminski told MD Magazine.

Since 1990, Dr. Kaminski has studied how marijuana impacts the immune system. In fact, according to the press release, he and his colleagues were the first “to identify the proteins that can bind marijuana compounds on the surface of immune cells,” whereas previous to this discovery, the impact of these compounds on the immune system was unknown.

For the current study, Dr. Kaminski and his team collected blood samples from 40 patients with HIV, some used marijuana, others did not. The team then isolated the monocytes from each patient to take a closer look at inflammatory cell levels and the impact of marijuana.

Their findings? The samples of those HIV patients who did not smoke marijuana contained “a very high level” of inflammatory cells compared with those who did smoke marijuana. “In fact, those who used marijuana had levels pretty close to a healthy person not infected with HIV,” Dr. Kaminski said in the press release. The compounds in marijuana acted as anti-inflammatory agents, reducing the number of monocytes within the patients.

“The anti-inflammatory properties were not novel,” Dr. Kaminski told MD Magazine. “What was novel was the rate of decrease of monocytes in these patients.”

Currently, medical marijuana is used to stimulate appetites, alleviate anxiety associated with HIV, or fight adverse effects caused by other therapies, Dr. Kaminski told MD Magazine.

A better understanding of how monocytes interact with marijuana could have potential implications for patients suffering from Alzheimer’s, Parkinson’s, or other neurological-related diseases since the same inflammatory cells are involved. Further research regarding this interaction could also potentially be used to inform the development of new therapeutic agents, such as a pill containing compounds derived from marijuana, that would help those living with HIV maintain their mental function.


Related to this article

Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.